Therapeutic Workshop Details
Autoimmune Disease: Rheumatoid Arthritis and Inflammatory Diseases - Clinical Perspective on New Treatment Paradigms and Targets
Thursday, October 11, 2007
3:30 PM
Twin Peaks South
Companies are focusing on advancing new treatment paradigms in arthritis and inflammatory diseases, based on the discovery of new molecular targets and pathways. Learn why these approaches may lead to more meaningful patient outcomes by taking into consideration the pathogenesis of chronic inflammatory diseases.
Moderators
- Gregory R. Wade, PhD; Senior Healthcare Research Analyst, Pacific Growth Equities, LLC
Panelists
- Theresa Podrebarac MD; MSc; Vice President Clinical Research, CombinatoRx, Inc.
- Edward W. Bernton, MD; Medical Director, Protalex, Inc.
- Douglas E. Williams, PhD; President and Chief Scientific Officer, ZymoGenetics, Inc.
- John Imboden, MD; Professor, Department of Medicine, Chief Division of Rheumatology, University of California, San Francisco
Who's Who
Gregory R. Wade, PhD, is a Research Analyst on the Healthcare Equity Research team and specializes in Biotechnology. He joined Pacific Growth in January 2000 from Isis Pharmaceuticals where he was the Associate Director of Business Development. Previous to that he was the Manager of Corporate Development for Procyon BioPharma, Inc., and with Helix Investments, Inc., a Toronto based venture capital firm. BS, Medical Biophysics: PhD, Physiology, University of Western Ontario.